文献一覧: 佐野栄紀 (著者)

4 0 0 0 本邦乾癬性関節炎患者の疫学調査~日本乾癬学会による3年間の集計結果~

著者: 山本俊幸大槻マミ太郎佐野栄紀森田明理奥山隆平五十嵐敦之川田暁
出版者: 公益社団法人日本皮膚科学会
雑誌: 日本皮膚科学会雑誌 (ISSN:0021499X)
巻号頁・発行日: vol.128, no.13, pp.2835-2841, 2018-12-20 (Released:2018-12-20)
参考文献数: 14

日本乾癬学会による,3年間の乾癬性関節炎疫学調査の結果をまとめた.本邦患者の臨床的特徴は,1)男性が女性の2倍弱多い,2)乾癬発症の平均年齢は30歳代後半,関節炎は40歳代後半,3)乾癬のタイプは尋常性(局面型)が9割以上,4)関節炎のタイプは,多関節炎型かDIP型が多い,5)乾癬の家族歴は5~7%程度,6)付着部炎は2割強,7)指趾炎は6割前後に認められる,などであった.生物学的製剤による治療は,約半数に導入されていたが,中止または他剤へのスイッチ例も15~20%強に認められた.爪病変,併存症,職業についても合わせて調査した.

2019-02-16 15:20:08
4 + 5 Twitter

4 0 0 0 乾癬における生物学的製剤の使用指針および安全対策マニュアル(2011年版)

著者: 大槻マミ太郎照井正小澤明森田明理佐野栄紀髙橋英俊小宮根真弓江藤隆史鳥居秀嗣朝比奈昭彦根本治中川秀己
出版者: 公益社団法人日本皮膚科学会
雑誌: 日本皮膚科学会雑誌 (ISSN:0021499X)
巻号頁・発行日: vol.121, no.8, pp.1561-1572, 2011-07-20 (Released:2014-11-13)

Clinical use of TNFα (tumor necrosis factor α) inhibitors, adalimumab and infliximab, for psoriasis began in January 2010 when an additional indication for this disease was approved. In January 2011, an interleukin-12/23 p40 (IL-12/23 p40) inhibitor, ustekinumab, was newly approved as the third biologic agent with an indication for psoriasis. All of these biologic agents are expected to exhibit excellent efficacy against not only psoriasis but also psoriatic arthritis, and to contribute to the improvement of quality of life (QOL) of psoriatic patients. At the same time, however, they require safety measures to prevent adverse drug reactions such as serious infections. We therefore decided to prepare this Guideline/Safety Manual for the Use of Biologic Agents in Psoriasis (The 2011 Version) by revising that for the use of TNFα Inhibitors prepared by the Biologics Review Committee of the Japanese Dermatological Association in February 2010. In this new unified version for all three biologic agents including ustekinumab, requirements for clinical facilities for the use of biologic agents, contents of safety measures against reactivation of tuberculosis and hepatitis B, and recommendable combination therapies with biologic agents, have been renewed and added. This guideline/safety manual has been prepared to assist dermatology specialists experienced in clinical practice of psoriasis to use biologic agents safely and properly.